Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPROVE: Biphasic Insulin Aspart 30 Titration in T2D
NCT00537277Phase 4Completed
- Sponsor
- Novo Nordisk
- Start
- Oct 2007
- Primary completion
- Jan 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Insulin aspart + insulin aspart protamine in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Primary endpoint: Percentage of Subjects Achieving the Treatment Target of Glycosylated Haemoglobin (HbA1c) Below 7.0% at 48 weeks. Started Oct 2007; status: completed.
02
Drugs
Insulin aspart + insulin aspart protamine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00537277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00537277.